Alkem Laboratories Limited

rs,

12th November, 2021 The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra K

₹ 28,000 million

umbai today. Key highlights of Q2FY22 financial performance  Total Revenue from Operations was ₹ 28,000 million, year-on-year growth of 18.5% India sales were ₹ 19,605 million, year-on-year growth of 25.9% Int

18.5%

inancial performance  Total Revenue from Operations was ₹ 28,000 million, year-on-year growth of 18.5% India sales were ₹ 19,605 million, year-on-year growth of 25.9% International sales were ₹ 8,052

₹ 19,605 million

Total Revenue from Operations was ₹ 28,000 million, year-on-year growth of 18.5% India sales were ₹ 19,605 million, year-on-year growth of 25.9% International sales were ₹ 8,052 million, year-on-year growth of 3.4

25.9%

00 million, year-on-year growth of 18.5% India sales were ₹ 19,605 million, year-on-year growth of 25.9% International sales were ₹ 8,052 million, year-on-year growth of 3.4% o o  Earnings before

₹ 8,052 million

of 18.5% India sales were ₹ 19,605 million, year-on-year growth of 25.9% International sales were ₹ 8,052 million, year-on-year growth of 3.4% o o  Earnings before Interest, Tax, Depreciation and Amortizati

3.4%

ion, year-on-year growth of 25.9% International sales were ₹ 8,052 million, year-on-year growth of 3.4% o o  Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 6,244 milli

₹ 6,244 million

rowth of 3.4% o o  Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 6,244 million, resulting in EBITDA margin of 22.3% vs. 25.4% in Q2FY21. EBITDA grew by 4.0% YoY  R&D expense

22.3%

t, Tax, Depreciation and Amortization (EBITDA) was ₹ 6,244 million, resulting in EBITDA margin of 22.3% vs. 25.4% in Q2FY21. EBITDA grew by 4.0% YoY  R&D expenses for the quarter was ₹ 1,407 million,

25.4%

preciation and Amortization (EBITDA) was ₹ 6,244 million, resulting in EBITDA margin of 22.3% vs. 25.4% in Q2FY21. EBITDA grew by 4.0% YoY  R&D expenses for the quarter was ₹ 1,407 million, or 5.0% of

4.0%

TDA) was ₹ 6,244 million, resulting in EBITDA margin of 22.3% vs. 25.4% in Q2FY21. EBITDA grew by 4.0% YoY  R&D expenses for the quarter was ₹ 1,407 million, or 5.0% of total revenue from operations

₹ 1,407 million

A margin of 22.3% vs. 25.4% in Q2FY21. EBITDA grew by 4.0% YoY  R&D expenses for the quarter was ₹ 1,407 million, or 5.0% of total revenue from operations compared to ₹ 1,393 million in Q2FY21 at 5.9% of total

Details of the conference call are as under

1

Dial in Details

1

Dial in Details

India : +91 22 6280 1149 / +91 22 7115 8050 International Toll Free USA UK Singapore Hong Kong : 1 866 746 2133 : 0 808 101 1573 : 800 101 2045 : 800 964 448 Express Join with Diamond Pass https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=5628564&linkS ecurityString=1603896b58 You are requested to dial in 10 mins ahead of the scheduled start time. A transcript of this conference call will also be available on our website www.alkemlabs.com About Alkem Laboratories Ltd. Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in